Ovagen: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 8 sources cited

Overview

Ovagen is a hepatoprotective bioregulator peptide (Glu-Asp-Leu) developed by the Khavinson laboratory in Russia. Its developers describe it as protecting both the liver and the kidneys, but the published experiments are in kidney cells and rat models of kidney injury; the liver claim rests on a patent, not a published study. As a short peptide bioregulator, it is proposed to work at the epigenetic level to restore normal protein synthesis patterns in aged or damaged tissue.

Mechanism of Action

Ovagen is a tripeptide proposed to enter cells and interact with specific DNA sequences; computer modeling predicts binding to the CTCC sequence and to AT-rich DNA. In aging kidney cell cultures it increased cell proliferation, lowered the aging markers p16, p21 and p53, raised SIRT-6 and changed MMP-14 expression. In rats with kidney injury it limited lipid peroxidation and preserved antioxidant enzyme activity. Effects on hepatocytes, cytochrome P450 enzymes, glutathione-S-transferase, albumin, bilirubin or bile acids have not been published. Like other Khavinson bioregulators, it is proposed to work through epigenetic modulation rather than receptor binding.

Ovagen Benefits: What the Research Shows

  • Khavinson et al. reported that the EDL peptide increased urine output and sodium excretion and raised antioxidant enzyme activity in the kidneys of old rats; no published study of hepatocyte function was found
  • Studies in Bulletin of Experimental Biology and Medicine showed the Glu-Asp-Leu tripeptide changed the expression of signaling molecules (MMP-14) in aging kidney cell cultures; liver cultures were not studied
  • Research demonstrated protection of kidney function in rat models of kidney injury (gentamicin, ischemia/reperfusion and cisplatin) after EDL treatment; no published study of liver function markers (ALT, AST, bilirubin) was found

Ovagen Dosage

  • Oral: 10–20 mg daily in capsule form for 10–30 days
  • Repeat cycles every 3–6 months for ongoing hepatoprotection
  • Can be taken with or without food
  • For active liver support: 20 mg daily for 30 days
  • For maintenance: 10 mg daily for 10–15 days every 4–6 months
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

Ovagen Side Effects & Safety

Known Side Effects

  • No published human research exists; the rat studies report no kidney toxicity
  • Mild GI discomfort — infrequently reported, generally with oral dosing
  • Effects on drug metabolism, including cytochrome P450 enzymes, have not been studied
  • Very limited safety data compared to pharmaceutical hepatoprotective agents

Safety Profile

Ovagen has not been studied in people; the research behind it is cell-culture and rat work by the Khavinson group and collaborators. As a naturally occurring tripeptide sequence, it is expected to have low toxicity. No adverse events have been reported, but no human study has been published in which they could have been recorded. No clinical trial of Ovagen was found, and the evidence comes from preclinical studies of kidney cells and rats. Individuals taking prescription medications should exercise caution, as Ovagen's effects on drug metabolism, including cytochrome P450 enzymes, have not been studied.

What to Expect

Days 1–10: No dramatic subjective effects expected. The peptide works at the epigenetic level, gradually modulating gene expression in hepatocytes. Days 10–30: No published study has measured liver function markers (ALT, AST) in people taking Ovagen. Some users report improved digestion and reduced sensitivity to alcohol. Post-cycle: Suppliers say benefits persist for weeks to months beyond the dosing period; this has not been studied, and changes in hepatocyte gene expression have not been shown.

Common Stacks

Storage & Handling

Store Ovagen capsules at room temperature (15–25°C) in a dry place away from direct sunlight. Shelf life is typically 2–3 years for encapsulated bioregulators. No refrigeration needed for the oral capsule form. Keep in original packaging to protect from moisture.

Pricing & Available Variants

$60price range
20mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Zamorskii II, Shchudrova TS, Lin'kova NS, et al. Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis. Bull Exp Biol Med. 2017.
  2. Zamorskii II, Shchudrova TS, Lin'kova NS, et al. Peptides Restore Functional State of the Kidneys During Cisplatin-Induced Acute Renal Failure. Bull Exp Biol Med. 2015.
  3. Zamorskii II, Shchudrova TS, Zeleniuk VG, et al. The influence of peptides on the morphofunctional state of old rats kidneys. Adv Gerontol. 2018.
  4. Khavinson VKh, Tarnovskaia SI, Lin'kova NS, et al. Tripeptides slow down aging process in renal cell culture. Adv Gerontol. 2014.
  5. Khavinson VKh, Lin'kova NS, Polyakova VO, et al. Peptides regulate expression of signaling molecules in kidney cell cultures during in vitro aging. Bull Exp Biol Med. 2014.
  6. Khavinson VK, Lin'kova NS, Tarnovskaya SI. Short Peptides Regulate Gene Expression. Bull Exp Biol Med. 2016.
  7. Khavinson V, Linkova N, Kozhevnikova E, et al. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. Int J Mol Sci. 2022.
  8. Khavinson VK, Popovich IG, Linkova NS, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021.

Related Peptides

Track Ovagen in Your Protocol

Log your Ovagen doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free